Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services that span the spectrum of the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Dysport/Azzalure, Alluzience, Restylane, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Metrics to compare | GALD | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipGALDPeersSector | |
---|---|---|---|---|
P/E Ratio | 98.6x | −0.1x | −0.5x | |
PEG Ratio | 0.20 | 0.00 | 0.00 | |
Price/Book | 2.9x | 1.3x | 2.6x | |
Price / LTM Sales | 5.1x | 1.7x | 2.9x | |
Upside (Analyst Target) | 35.8% | 82.7% | 66.2% | |
Fair Value Upside | Unlock | 11.0% | 10.3% | Unlock |